GreenCross Medical Science Corp. announced that it expects to receive KRW 10 billion in funding from Kiwoom Securities Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, Industrial Bank of Korea, Investment Arm, and other investors
January 02, 2018
Share
GreenCross Medical Science Corp. (KOSDAQ:A142280) announced a private placement of second series unregistered unsecured unguaranteed private convertible bonds for gross proceeds of KRW 10,000,000,000 on January 3, 2018. The transaction will include participation from new investors, Kiwoom Securities Co., Ltd., Investment Arm for KRW 3,000,000,000, Korea Investment & Securities Co., Ltd., Investment Arm for KRW 2,000,000,000, Industrial Bank of Korea, Investment Arm for KRW 2,000,000,000, and other two investors. The company will issue bonds at par. The bonds carry zero coupon rate and zero yield to maturity. The bonds carry maturity date of January 5, 2023. The bonds are convertible into common shares of the company at a fixed conversion price of KRW 12,220 per share from January 5, 2019 to December 5, 2022. The payment date is January 5, 2018. The transaction has been approved by the board of directors of the company.
Green Cross Medical Science Corporation is a Korea-based company principally engaged in the medical business. The Company mainly operates its business through three segments: diagnosis reagent segment, blood bag segment and blood dialysate segment. Its diagnosis reagent segment provides in vitro diagnosis reagents and medical equipment. Its blood bag segment provides filter bags and blood bags. The Company distributes its products within domestic market and to overseas markets.
GreenCross Medical Science Corp. announced that it expects to receive KRW 10 billion in funding from Kiwoom Securities Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, Industrial Bank of Korea, Investment Arm, and other investors